Targretin

Targretin is a brand name of bexarotene, approved by the FDA in the following formulation(s):

TARGRETIN (bexarotene - capsule; oral)

• 
  Manufacturer: EISAI INC
  
  Approval date: December 29, 1999
  
  Strength(s): 75MG ^[RLD]

Has a generic version of Targretin been approved?

No. There is currently no therapeutically equivalent version of Targretin available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Targretin. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Compounds having selective activity for Retinoid X Receptors, and means for modulation of processes mediated by Retinoid X Receptors
  Patent 5,780,676
  Issued: July 14, 1998
  Inventor(s): Boehm; Marcus F. & Heyman; Richard A. & Zhi; Lin & Hwang; Chan Kou & White; Steve & Nadzan; Alex
  Assignee(s): Ligand Pharmaceuticals Incorporated
  Compounds, compositions, and methods for modulating processes mediated by Retinoid X Receptors using retinoid-like compounds which have activity selective for members of the subclass of Retinoid X Receptors (RXRs), in preference to members of the subclass of Retinoic Acid Receptors (RARs). Examples of such compounds are bicyclic benzyl, pyridinyl, thiophene, furanyl, pyrrole, and poiyenoic acid derivatives including carbocyclic polyenoic acids. The disclosed methods employ compounds for modulating processes selectively mediated by Retinoid X Receptors.
  
  Patent expiration dates:
  
  
  • July 14, 2015
    
    ✓ 
    Patent use: TREATMENT OF CUTANEOUS MANIFESTATIONS OF CUTANEOUS T-CELL LYMPHOMA IN PATIENTS WHO ARE REFRACTORY TO AT LEAST ONE PRIOR SYSTEMIC THERAPY
  
  



• 
  Compounds having selective activity for retinoid X receptors, and means for modulation of processes mediated by retinoid X receptors
  Patent 5,962,731
  Issued: October 5, 1999
  Inventor(s): Boehm; Marcus F. & Heyman; Richard A.
  Assignee(s): Ligand Pharmaceuticals Incorporated
  Compounds, compositions, and methods for modulating processes mediated by Retinoid X Receptors using retinoid-like compounds which have activity selective for members of the subclass of Retinoid X Receptors (RXRs), in preference to members of the subclass of Retinoic Acid Receptors (RARs). Examples of such compounds are bicyclic benzyl, pyridinyl, thiophene, furanyl, and pyrrole derivatives. The disclosed methods employ compounds for modulating processes selectively mediated by Retinoid X Receptors.
  
  Patent expiration dates:
  
  
  • October 5, 2016
    
    ✓ 
    Patent use: TREATMENT OF CUTANEOUS MANIFESTATIONS OF CUTANEOUS T-CELL LYMPHOMA IN PATIENTS WHO ARE REFRACTORY TO AT LEAST ONE PRIOR SYSTEMIC THERAPY
  
  



• 
  Compounds having selective activity for retinoid X receptors, and means for modulation of processes mediated by retinoid X receptors
  Patent 6,043,279
  Issued: March 28, 2000
  Inventor(s): Boehm; Marcus F. & Heyman; Richard A.
  Assignee(s): Ligand Pharmaceuticals, Incorporated
  Compounds, compositions, and methods for modulating processes mediated by Retinoid X Receptors using retinoid-like compounds which have activity selective for members of the subclass of Retinoid X Receptors (RXRs), in preference to members of the subclass of Retinoic Acid Receptors (RARs). Examples of such compounds are bicyclic benzyl, pyridinyl, thiophene, furanyl, and pyrrole derivatives. The disclosed methods employ compounds for modulating processes selectively mediated by Retinoid X Receptors.
  
  Patent expiration dates:
  
  
  • April 22, 2012
    
    ✓ 
    Patent use: TREATMENT OF CUTANEOUS MANIFESTATIONS OF CUTANEOUS T-CELL LYMPHOMA IN PATIENTS WHO ARE REFRACTORY TO AT LEAST ONE PRIOR SYSTEMIC THERAPY
  
  



• 
  Compounds having selective activity for retinoid X receptors, and means for modulation of processes mediated by retinoid X receptors
  Patent 6,320,074
  Issued: November 20, 2001
  Inventor(s): Boehm; Marcus F. & Heyman; Richard A. & Zhi; Lin & Koch; Stacie Canan
  Assignee(s): Ligand Pharmaceuticals Incorporated
  Compounds, compositions, and methods for modulating processes mediated by Retinoid X Receptors using retinoid-like compounds which have activity selective for members of the subclass of Retinoid X Receptors (RXRs), in preference to members of the subclass of Retinoic Acid Receptors (RARs). Examples of such compounds are bicyclic benzyl, pyridinyl, thiophene, furanyl, and pyrrole derivatives. The disclosed methods employ compounds for modulating processes selectively mediated by Retinoid X Receptors.
  
  Patent expiration dates:
  
  
  • April 22, 2012
    
    ✓ 
    Patent use: TREATMENT OF CUTANEOUS MANIFESTATIONS OF CUTANEOUS T-CELL LYMPHOMA IN PATIENTS WHO ARE REFRACTORY TO AT LEAST ONE PRIOR SYSTEMIC THERAPY
    ✓ 
    Drug substance
  
  



• 
  Compounds having selective activity for retinoid X receptors, and means for modulation of processes mediated by retinoid X receptors
  Patent 7,655,699
  Issued: February 2, 2010
  Inventor(s): Boehm; Marcus F. & Heyman; Richard A.
  Assignee(s): Eisai Inc.
  Compounds, compositions, and methods for modulating processes mediated by Retinoid X Receptors using retinoid-like compounds which have activity selective for members of the subclass of Retinoid X Receptors (RXRs), in preference to members of the subclass of Retinoic Acid Receptors (RARs). Examples of such compounds are bicyclic benzyl, pyridinyl, thiophene, furanyl, pyrrole, and polyenoic acid derivatives including carbocyclic polyenoic acids. The disclosed methods employ compounds for modulating processes selectively mediated by Retinoid X Receptors.
  
  Patent expiration dates:
  
  
  • April 22, 2012
    
    ✓ 
    Patent use: TREATMENT OF CUTANEOUS MANIFESTATIONS OF CUTANEOUS T-CELL LYMPHOMA IN PATIENTS WHO ARE REFRACTORY TO AT LEAST ONE PRIOR SYSTEMIC THERAPY
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  

See also...

• Targretin Consumer Information (Wolters Kluwer)
• Targretin Consumer Information (Cerner Multum)
• Targretin Advanced Consumer Information (Micromedex)
• Targretin AHFS DI Monographs (ASHP)
• Bexarotene Consumer Information (Wolters Kluwer)
• Bexarotene Consumer Information (Cerner Multum)
• Bexarotene Advanced Consumer Information (Micromedex)
• Bexarotene AHFS DI Monographs (ASHP)